Table 3 Observed versus expected receipt of focus drug in 2014
From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Region | Docetaxel (%) | Cabazitaxel (%) | Sipuleucel-T (%) | Radium-223 (%) | Abiraterone (%) | Enzalutamide (%) | Row Total |
|---|---|---|---|---|---|---|---|
New England | 12 (27.3) | 0 (0.0) | 3 (6.8) | 0 (0.0) | 22 (50.0) | 7 (15.9) | 44 |
11 | 0 | 4 | 1 | 20 | 8 | ||
Middle Atlantic | 23 (21.5) | 0 (0.0) | 6 (5.6) | 3 (2.8) | 50 (46.7) | 25 (23.4) | 107 |
26 | 0 | 10 | 1 | 50 | 20 | ||
South Atlantic | 44 (26.0) | 0 (0.0) | 20 (11.8) | 2 (1.2) | 70 (41.4) | 33 (19.5) | 169 |
41 | 0 | 16 | 2 | 78 | 32 | ||
East North Central | 38 (22.0) | 3 (1.7) | 17 (9.8) | 2 (1.2) | 73 (42.2) | 40 (23.1) | 173 |
42 | 0 | 16 | 2 | 79 | 33 | ||
East South Central | 5 (14.7) | 0 (0.0) | 4 (11.8) | 0 (0.0) | 19 (55.9) | 6 (17.6) | 34 |
8 | 0 | 3 | 0 | 16 | 6 | ||
West North Central | 39 (45.3) | 0 (0.0) | 12 (14.0) | 3 (3.5) | 23 (26.7) | 9 (10.5) | 86 |
21 | 0 | 8 | 1 | 39 | 16 | ||
West South Central | 20 (21.1) | 0 (0.0) | 9 (9.5) | 1 (1.1) | 46 (48.4) | 19 (20.0) | 95 |
23 | 0 | 9 | 1 | 44 | 18 | ||
Mountain | 26 (21.1) | 0 (0.0) | 13 (10.6) | 0 (0.0) | 64 (52.0) | 20 (16.3) | 123 |
30 | 1 | 12 | 1 | 56 | 23 | ||
Pacific | 23 (15.6) | 0 (0.0) | 5 (3.4) | 0 (0.0) | 91 (61.9) | 28 (19.0) | 147 |
36 | 1 | 14 | 2 | 67 | 28 | ||
Unknown | 25 (37.3) | 1 (1.5) | 9 (13.4) | 1 (1.5) | 21 (31.3) | 10 (14.9) | 67 |
16 | 0 | 6 | 1 | 31 | 13 | ||
Column Total | 255 | 4 | 98 | 12 | 479 | 197 | 1045 |